FDA panel recommends two drugs for rare form of pancreatic cancer
Wednesday, April 13, 2011 - 00:30
in Health & Medicine
The panel finds that the benefits of Novartis' Afinitor and Pfizer's Sutent outweigh their side effects in treating pancreatic neuroendocrine tumors.Two drugs used against kidney cancer won the endorsement of a federal advisory panel Tuesday to treat a form of pancreatic cancer that strikes several hundred Americans each year.